Connective Tissue Diseases clinical trials at University of California Health
3 in progress, 2 open to eligible people
Ralinepag to Improve Treatment Outcomes in PAH Patients
open to eligible people ages 18 years and up
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
at UC Davis UC Irvine UCLA UCSD
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
open to eligible people ages 18-80
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
at UCLA
Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
at UC Davis UC Irvine UCLA UCSD
Our lead scientists for Connective Tissue Diseases research studies include Suzanne Kafaja Timothy Fernandes, MD Bassam Yaghmour, MD Rajan Saggar Namita Sood, MD.
Last updated: